SPRY3 Antibody

What is SPRY3 and why is it significant in research?

SPRY3 (Sprouty homolog 3) is a member of the sprouty family of proteins that function as regulators of cell growth and branching morphogenesis. SPRY3 appears to modulate Ras/MAPK pathway signaling following receptor tyrosine kinase (RTK) activation . It has been implicated in brain cancer development, affecting cell proliferation and migration . SPRY3 is particularly significant in neuroscience research as it is expressed specifically in neuronal cells and plays a role in motor axon development .

What applications are SPRY3 antibodies validated for?

SPRY3 antibodies have been validated for multiple research applications including:

• Western Blot (WB): Most commonly validated application with dilution ranges of 1:500-1:2000

• Immunohistochemistry (IHC): Validated for detection in tissue sections

• Immunocytochemistry (ICC): For cellular localization studies

• Immunoprecipitation (IP): For protein-protein interaction studies

• ELISA: Some antibodies are validated for this application

What is the expected molecular weight for SPRY3 detection in Western blots?

The molecular weight detection for SPRY3 varies slightly between antibodies and experimental conditions:

• Calculated molecular weight: 31 kDa based on 288 amino acids

• Observed molecular weight range: 31-33 kDa in many experimental systems

• Some antibodies detect SPRY3 at approximately 42 kDa, as seen in HepG2 and MCF-7 cell lines

This variation could be due to post-translational modifications, different isoforms, or experimental conditions.

How should I determine the optimal antibody dilution for my experimental system?

Determining the optimal antibody dilution requires systematic titration:

• Begin with the manufacturer's recommended dilution range (e.g., 1:500-1:2000 for Western blot)

• Perform a dilution series experiment with your specific sample type

• Include proper positive controls (e.g., RAW 264.7 cells, HepG2 cells, or MCF-7 cells)

• Consider that optimal dilution may be sample-dependent as noted in product documentation

• For Western blot optimization, test different blocking agents and incubation times

• Document band intensity and background signal at each dilution

Remember that "it is recommended that this reagent should be titrated in each testing system to obtain optimal results" .

What are the recommended buffer conditions for SPRY3 antibody storage and use?

Based on manufacturer recommendations:

Important considerations:

• Use a manual defrost freezer and avoid repeated freeze-thaw cycles

• Aliquoting is generally unnecessary for -20°C storage for some formulations

• Some 20μl size formulations contain 0.1% BSA as a stabilizer

What cell lines have been validated as positive controls for SPRY3 detection?

The following cell lines have been experimentally validated as positive controls for SPRY3 detection:

For neuronal studies, cerebellum tissue samples (particularly Purkinje cells) serve as excellent positive controls due to high endogenous SPRY3 expression .

How can I study SPRY3 function through overexpression and knockdown approaches?

Research has employed several methodological approaches for functional SPRY3 studies:

Overexpression methodology:

• Cloning the SPRY3 open reading frame (ORF) into expression vectors (e.g., pQE-Tri System vector using NcoI and PmlI sites)

• Sequence verification of the insert and flanking regions

• Transfection into appropriate cell lines (HeLa cells have been used successfully)

• Confirmation of expression by Western blot analysis using anti-SPRY3 antibody

Knockdown methodology:

• Design of shRNA constructs targeting specific SPRY3 sequences:

  • Example targeting sequence used in research: 5′-TCG AGC GCA GCT GTT CAA TAG GCA GAA TTT GTT GAA GCT TGA ACA AAT TCT GCC TAT TGA ACA GCT GCG CTC TTT TTT-3′

• Cloning into appropriate vectors (e.g., pADloxU6 vector) or pSicoR-based vectors

• Validation of knockdown efficiency by co-transfection with SPRY3 expression vectors

• Quantification of knockdown using qRT-PCR with SPRY3-specific primers

• Assessment of cell viability using MTT assay at 24 and 48 hours post-transfection

For developmental studies, morpholino-based knockdown in model organisms like Xenopus has been effective for studying neuronal development .

What experimental approaches can elucidate SPRY3's role in neuronal development?

Based on published methodologies:

• Expression analysis in nervous system:

  • qRT-PCR comparison of SPRY3 mRNA levels across brain regions and developmental stages

  • Immunohistochemistry of brain sections to localize SPRY3 protein

  • Western blot analysis to quantify relative protein levels between brain regions

• Functional analysis in neuronal models:

  • Morpholino-based knockdown in developmental models (e.g., Xenopus)

  • Analysis of motor axon organization using anti-acetylated α-tubulin antibody staining

  • Control verification using muscle-specific antibodies (e.g., 12-101)

  • Quantification of differentiating neurons using anti-Myt1 antibodies

  • Primary neuronal cultures (e.g., superior cervical ganglion cells) for neurite growth and branching studies

• Signaling pathway analysis:

  • Examination of Ca²⁺ pathway response to BDNF stimulation

  • Monitoring ERK activation status in response to growth factor treatment

  • Comparison with related inhibitors like Spred1

How does SPRY3 function differ from other Sprouty family members in signaling pathway regulation?

SPRY3 demonstrates both similarities and differences compared to other Sprouty family members:

• Pathway specificity:

  • SPRY3 can inhibit the Ca²⁺ pathway in response to BDNF

  • SPRY3 reduces ERK activation downstream of BDNF, though its inhibitory action is not as strong as Spred1

  • Unlike SPRY4, which inhibits VEGF-A signaling via PLCγ, the exact mechanism of SPRY3's inhibition of ERK activation remains undetermined

• Cellular context specificity:

  • SPRY3 does not inhibit ERK activation in mammalian cell lines, suggesting context-dependent function

  • SPRY3 forms homo- and hetero-oligomers with other SPRY family molecules

• Post-translational modifications:

  • SPRY3 undergoes phosphorylation, ubiquitination and palmitoylation

  • Palmitoylation specifically induces SPRY3 to associate with cell membranes

• Functional studies in FGF signaling:

  • In U373 cells, FGF induces MAPK pathway activation after 10 minutes

  • Cells expressing excess SPRY3 show less pronounced phosphorylation of ERK in response to FGF

  • SPRY3's response to FGF differs from SPRY4, which shows distinct patterns of pERK inhibition

What factors might affect SPRY3 antibody specificity and how can I validate antibody specificity?

To ensure SPRY3 antibody specificity:

• Common specificity issues:

  • Cross-reactivity with other Sprouty family members

  • Non-specific binding to similar epitopes

  • Background signal in specific tissue types

• Validation approaches:

  • Use decreasing amounts of SPRY3-expressing adenovirus to test antibody sensitivity

  • Compare detection across all four Sprouty proteins (SPRY1-4) expressed ectopically to confirm specificity

  • Include appropriate negative controls (tissue/cells with low SPRY3 expression)

  • Use SPRY3 knockdown samples as specificity controls

  • Western blot analysis should detect a single band at the expected molecular weight (31-33 kDa or 42 kDa depending on the antibody)

• Sample preparation considerations:

  • For Western blot, reducing conditions have been successfully used

  • Follow manufacturer-specific buffer recommendations (e.g., Immunoblot Buffer Group 1)

How can I differentiate between different SPRY3 transcript variants in experimental analysis?

Research has developed specific strategies for differentiating SPRY3 transcript variants:

• qRT-PCR approach:

  • Design primers targeting specific regions unique to each variant

  • For example, designing a reverse primer in the 150 bp region between the SPRY3 PAR2-linked promoter TSS and the SPRY3 exon 1 splice acceptor site allows separate amplification of SPRY3_V1 from SPRY3_V2 & V3 transcripts

• Primer design strategy:

  • Total SPRY3 expression: primers targeting common regions

  • SPRY3_V1 expression: primers specific to this variant

  • SPRY3_V2 expression: primers specific to this variant

  • SPRY3_V3 expression: derived by subtraction

• Control strategy:

  • Create a vector containing subcloned copies of multiple SPRY3 transcripts to normalize the relative efficiencies of different PCR primer pairs

• Considerations for complex splicing:

  • SPRY3_V3 transcripts have complex splicing patterns with variable inclusion of multiple alternative exons

  • Some transcripts may terminate at exon 4 of DB209851, complicating quantification

What controls should be included when analyzing SPRY3 expression across different tissue types?

For robust SPRY3 expression analysis across tissues:

• Positive controls:

  • Cerebellum tissue (particularly Purkinje cells) - shows 3-4 fold higher expression than other brain regions

  • Superior cervical ganglion (SCG) and dorsal root ganglion (DRG) - show robust expression

  • Retinal ganglion cell layer (GCL) and inner nuclear layer (INL) - show intense staining

  • Validated cell lines: RAW 264.7, HepG2, MCF-7

• Negative controls:

  • Non-neural tissues (show relatively low expression)

  • Isotype-matched irrelevant antibody controls

  • Secondary antibody-only controls

• Loading controls for Western blot:

  • GAPDH and ERK 1/2 have been successfully used as loading controls in SPRY3 studies

• Normalization for qRT-PCR:

  • Use validated housekeeping genes appropriate for the tissues being compared

  • For transcript variant analysis, use a vector containing subcloned copies of SPRY3 transcripts to normalize primer efficiency

How does SPRY3 expression change during development and across different neuronal cell types?

SPRY3 shows specific developmental and cell-type expression patterns:

• Developmental timepoints:

  • Expression can be detected in neonatal (P1), recently weaned (P21), and adult stages

  • Cerebellar expression is approximately 3-4 fold higher than other brain regions across postnatal and adult stages

• Neural cell type specificity:

  • Cerebellar Purkinje cells show intense SPRY3 expression

  • Retinal ganglion cell layer (GCL) and inner nuclear layer (INL) exhibit strong expression

  • Superior cervical ganglion (SCG) and dorsal root ganglion (DRG) show robust staining

  • Conservation of expression pattern has been documented between mouse and human cerebellar Purkinje cells

• Quantification approaches:

  • qRT-PCR for mRNA level comparison across brain regions

  • Western blot for protein level comparison

  • Immunohistochemistry for cellular and subcellular localization

What methodological approaches can determine if SPRY3 alterations contribute to disease pathology?

Based on existing research frameworks:

• Expression analysis in disease models:

  • Analysis of SPRY3 expression influence by grade of malignancy in brain cancer-derived cells

  • Production, affinity-purification and validation of antibody specificity and sensitivity are critical steps

  • Infection of cells with decreasing titers of SPRY3-encoding adenoviruses to establish expression-signal relationships

• Functional assessment:

  • Examination of SPRY3's interference with FGF-induced signaling in serum-deprived conditions

  • Monitoring pERK levels following growth factor addition in cells with normal versus altered SPRY3 expression

  • Analysis of cell proliferation and migration in models with perturbed SPRY3 function

• Molecular pathway analysis:

  • Study of MAPK pathway activation timing and extent in control versus SPRY3-overexpressing cells

  • Comparative analysis with other Sprouty family members (e.g., SPRY4) to identify unique roles

The research suggests "Spry3 and Spry4 expression may be altered in brain cancer and affect cell proliferation and migration" , providing methodological frameworks for investigating disease relevance.